Friday, 16 October 2026European Markets

BW OFFSHORE LTD Stock Over 11% Up So Far On Friday

Loading stream...

(VIANEWS) - Shares of BW OFFSHORE LTD (Oslo Børs Benchmark Index_GI: BWO.OL) rose by a staggering 11.31% to kr29.52 at 13:24 EST on Friday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is sliding 0.66% to kr1,225.46, after four consecutive sessions in a row of losses. This seems, up until now, a somewhat down trend trading session today.

About BW OFFSHORE LTD

BW Offshore Limited engages in the engineering of offshore production solutions in the Americas, Europe, Africa, Asia, and the Pacific. The company builds, owns, leases, and operates floating, production, storage, and offloading vessels (FPSOs) for oil and gas industries. It also provides engineering and management services. As of December 31, 2021, the company operated nine FPSOs. BW Offshore Limited was founded in 1982 and is based in Hamilton, Bermuda.

Earnings Per Share

As for profitability, BW OFFSHORE LTD has a trailing twelve months EPS of kr-12.5.

Volatility

BW OFFSHORE LTD's last week, last month's, and last quarter's current intraday variation average was a negative 1.25%, a positive 0.24%, and a positive 1.56%.

BW OFFSHORE LTD's highest amplitude of average volatility was 1.39% (last week), 1.50% (last month), and 1.56% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BW OFFSHORE LTD's stock is considered to be overbought (>=80).

More news about BW OFFSHORE LTD (BWO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com